Online citations, reference lists, and bibliographies.
← Back to Search

Systematic Development Of Sertraline Loaded Solid Lipid Nanoparticle (SLN) By Emulsification-ultrasonication Method And Pharmacokinetic Study In Sprague-Dawley Rats.

Md Akhlaquer Rahman, R. K. Harwansh, Z. Iqbal
Published 2019 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
In the current research (i) solid lipid nanoparticles (SLN) were systematically developed by emulsification-ultrasonication method, and (ii) pharmacokinetic parameters were obtained after oral administration of a single dose of optimized SLN formulation and aqueous suspension of sertraline. Different batches were prepared by changing process parameters, and finally on the basis of nanoparticle size, size distribution i.e. polydispersity index (PDI), zeta potential (ZP), encapsulation efficiency (EE), and drug loading capacity (L) an optimum system was designed. The optimized formulation contains; 5% (w/v) Compritol® E ATO as lipids, 2.5% (w/v) Tween® 80 as surfactant and 0.1% (w/v) SRT as actives. The formulation was freeze-dried using mannitol as a cryoprotectant to control the aggregation of particles during redispersion process. SLNs with <110 nm size, <0.2 PDI, >36 mV ZP, >72% EE, and nearly 0.7% L can be formed at appropriate formulation process conditions; homogenization time (HT) and sonication time (ST) at 5 min and 10 min, respectively. XRD studies indicated the presence of amorphous form of drug that is completely encapsulation within the nanoparticulate matrix system. The optimized SLN formulation have shown the highest value of zeta potential (-36.5 mV) confers stability of nanodispersion. Release of drug encapsulated in SLN showed a biphasic pattern and was extended upto 12 hours. The maximum plasma concentration (Cmax) and area under the curve (AUC) in case of sertraline loaded SLN were found 10-fold and 6-fold higher, respectively compared to pure drug. The result depicted enhanced extent of absorption of sertraline from SLN compared to plain sertraline. Furthermore, sertraline-loaded SLN were found to be stable at 4 °C for 6 months of study period. Hence, the SLN can be used as a potential carrier for successful delivery of poorly water-soluble drugs associated with poor oral bioavailability like sertraline.
This paper references
10.1007/s40005-016-0263-y
Development and pharmacokinetic evaluation of spray-dried self-nanoemulsifying drug delivery system of sertraline
M. A. Rahman (2016)
10.1016/j.ijpharm.2009.08.035
Self-nanoemulsifying drug delivery system (SNEDDS) for oral delivery of Zedoary essential oil: formulation and bioavailability studies.
Y. Zhao (2010)
10.1016/j.jconrel.2008.10.002
Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles.
Houli Li (2009)
10.1016/j.ejpb.2009.06.001
Lipid--an emerging platform for oral delivery of drugs with poor bioavailability.
S. Chakraborty (2009)
10.3797/scipharm.1105-09
Functions of Lipids for Enhancement of Oral Bioavailability of Poorly Water-Soluble Drugs
B. K. Nanjwade (2011)
10.1007/s11095-008-9677-1
The Impact of Aqueous Solubility and Dose on the Pharmacokinetic Profiles of Resveratrol
S. Das (2008)
10.1016/S0378-5173(96)04822-3
Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles
R. Cavalli (1997)
Nano and microparticles as controlled drug delivery devices.
Ravi Kumar M.N.V. (2000)
10.1080/02652040010018056
Production of solid lipid nanoparticles (SLN): scaling up feasibilities
A. Dingler (2002)
10.1016/S0009-9236(03)00059-6
Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40
Y. Tayrouz (2003)
10.1016/S0939-6411(00)00087-4
Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.
R. Mueller (2000)
10.1016/0378-5173(93)90177-H
Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction
K. Westesen (1993)
10.1016/S0378-5173(98)00404-9
Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures.
C. Olbrich (1999)
10.1016/j.steroids.2015.05.012
Design, characterization and skin permeating potential of Fluocinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis
M. Pradhan (2015)
10.1211/0022357044959
Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs
L. Hu (2004)
10.1016/J.IJPHARM.2006.08.007
Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery.
J. Liu (2007)
10.2174/156720110791011783
Novel drug delivery systems for sustained and targeted delivery of anti- cancer drugs: current status and future prospects.
Puneet Utreja (2010)
10.1016/j.colsurfb.2010.12.014
Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acids.
Shuyu Xie (2011)
10.1016/j.ejps.2009.04.008
Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin.
Robhash Kusam Subedi (2009)
10.1016/j.jconrel.2007.12.018
Potential of solid lipid nanoparticles in brain targeting.
I. P. Kaur (2008)
10.1016/J.EJPS.2006.04.016
Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system.
C. Pouton (2006)
10.3109/10611869609015973
Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407.
R. Mueller (1996)
10.1358/MF.2005.27.2.876286
Solid lipid nanoparticles as drug delivery systems.
K. Manjunath (2005)
10.1080/03639040600814676
Formulation and Evaluation of Nanostructured Lipid Carrier (NLC)–based Gel of Valdecoxib
M. Joshi (2006)
10.1016/j.ejpb.2008.09.015
Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy.
A. Del Pozo-Rodríguez (2009)
10.1016/S0378-5173(97)00222-6
Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN).
Schwarz (1997)
10.1208/s12249-010-9563-0
Recent Advances in Lipid Nanoparticle Formulations with Solid Matrix for Oral Drug Delivery
S. Das (2010)
10.1016/J.EJPS.2004.10.008
Preparation and characterization of solid lipid nanoparticles (SLN) made of cacao butter and curdlan.
Byung-Do Kim (2005)
10.3109/21691401.2014.955105
Influence of selected variables on fabrication of Triamcinolone acetonide loaded solid lipid nanoparticles for topical treatment of dermal disorders
M. Pradhan (2016)
10.1016/S0928-0987(01)00186-5
Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats.
R. Holm (2001)
10.1016/j.jcis.2009.03.012
Effect of surfactant surface coverage on formation of solid lipid nanoparticles (SLN).
T. Helgason (2009)
10.1016/j.ijpharm.2011.04.041
Oil based nanocarrier for improved oral delivery of silymarin: In vitro and in vivo studies.
R. Parveen (2011)
10.1016/J.IJPHARM.2006.02.045
Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
R. Mueller (2006)
Scaling up feasibility of the production of solid lipid nanoparticles (SLN).
S. Gohla (2001)
10.1016/j.nano.2008.12.003
PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation.
M. Muthu (2009)
10.1016/J.COLSURFB.2007.03.002
Studies on oral absorption of stearic acid SLN by a novel fluorometric method.
H. Yuan (2007)
10.1016/J.JCONREL.2004.01.005
Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles.
V. Venkateswarlu (2004)
10.1016/S0939-6411(02)00196-0
A study of the freeze-drying conditions of calixarene based solid lipid nanoparticles.
P. Shahgaldian (2003)
10.1016/0378-5173(94)00347-8
Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix
K. Westesen (1995)
10.1590/S2175-97902018000117232
Development of self-nanoemulsifying tablet (SNET) for bioavailability enhancement of sertraline
M. A. Rahman (2018)
10.1038/nrd2197
Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
C. H. Porter (2007)
10.1016/j.ejpb.2009.12.008
Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics.
C. Chen (2010)
10.1016/S0169-409X(01)00105-3
Solid lipid nanoparticles: production, characterization and applications.
W. Mehnert (2001)
10.1016/j.colsurfb.2011.07.036
Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables.
S. Das (2011)
10.1007/978-3-642-37555-2
Protein-Nanoparticle Interactions
M. Rahman (2013)
10.1016/J.COLSURFB.2007.07.015
Solid lipid nanoparticles prepared by solvent diffusion method in a nanoreactor system.
H. Yuan (2008)
10.1023/A:1020311127328
Structured Triglyceride Vehicles for Oral Delivery of Halofantrine: Examination of Intestinal Lymphatic Transport and Bioavailability in Conscious Rats
R. Holm (2004)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar